YU49995A - POLYNUCLEOTIDE VACCINE FOR HERPES VIRUS - Google Patents
POLYNUCLEOTIDE VACCINE FOR HERPES VIRUSInfo
- Publication number
- YU49995A YU49995A YU49995A YU49995A YU49995A YU 49995 A YU49995 A YU 49995A YU 49995 A YU49995 A YU 49995A YU 49995 A YU49995 A YU 49995A YU 49995 A YU49995 A YU 49995A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- hsv
- pnv
- immunization
- animals
- herpes virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
POLINUKLEOTIDNA VAKCINA ZA VIRUS HERPESA - Geni koji kodiraju proteine herpes simpleks virusa tipa 2 (HSV-2) se kloniraju u eukariotične ekspresione vaktore da bi ekspresionisali kodirane proteine in vivo i mišićne delije sisara. Životinje se imuniziraju injekcijom ovih DNK konstrukcija, nazvanih polinukleotidne vakcine ili PNV, u njihove mi'Side. U DNK titraciji nadeno je da jedna imunizacija od. 0.5 "F128M".m"F255D".g fledne PNV daje 90% serokonverzije za deset nedelja posle imunizacije. Imuni antiserumi neutralist i HSV-2 i HSV-1 u ćelijskoj kulturi. Kad se životinje izazovu sa HSV-2 postignuta je značajna (p .001) zaštita od letalne infekcije posle PNV vakcinacije.HERPES VIRUS POLYNUCLEOTIDE VACCINE - Genes encoding herpes simplex virus type 2 (HSV-2) proteins are cloned into eukaryotic expression vactors to express encoded proteins in vivo and mammalian muscle cells. Animals are immunized by injecting these DNA constructs, called polynucleotide vaccines or PNVs, into their muscles. In DNA titration it was found that one immunization of. 0.5 "F128M" .m "F255D" .g fledne PNV gives 90% seroconversion in ten weeks after immunization. Immune antiserums neutralize both HSV-2 and HSV-1 in cell culture. When animals were challenged with HSV-2, significant (p .001) protection against lethal infection was achieved after PNV vaccination.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27945994A | 1994-07-22 | 1994-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU49995A true YU49995A (en) | 1998-05-15 |
Family
ID=23069059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU49995A YU49995A (en) | 1994-07-22 | 1995-07-21 | POLYNUCLEOTIDE VACCINE FOR HERPES VIRUS |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0772680A1 (en) |
JP (1) | JPH10503649A (en) |
AU (1) | AU708460B2 (en) |
CA (1) | CA2195099A1 (en) |
CO (1) | CO4410257A1 (en) |
HR (1) | HRP950412A2 (en) |
IL (1) | IL114576A0 (en) |
WO (1) | WO1996003510A1 (en) |
YU (1) | YU49995A (en) |
ZA (1) | ZA956106B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
WO1998014586A1 (en) * | 1996-10-01 | 1998-04-09 | Merck & Co., Inc. | A polynucleotide herpes virus vaccine |
AU738835B2 (en) * | 1994-07-22 | 2001-09-27 | Merck & Co., Inc. | A polynucleotide herpes virus vaccine |
US7094767B2 (en) | 1994-07-22 | 2006-08-22 | Merck & Co., Inc. | Polynucleotide herpes virus vaccine |
EP0931156A2 (en) * | 1996-10-18 | 1999-07-28 | Valentis Inc. | Gene expression and delivery systems and uses |
CA2268365A1 (en) * | 1996-10-18 | 1998-04-30 | Jeff Nordstrom | Il-12 gene expression and delivery systems and uses |
GB9720633D0 (en) * | 1997-09-29 | 1997-11-26 | Univ Bristol | BHV-2 vector |
US6488936B1 (en) * | 1998-02-12 | 2002-12-03 | Wyeth | Immunogenic composition of interleukin-12 (IL-12), alum, herpes simplex viral (HSV) antigen, and method thereof |
US6867000B2 (en) * | 2000-12-07 | 2005-03-15 | Wyeth Holdings Corporation | Method of enhancing immune responses to herpes |
US9012349B1 (en) | 2013-11-01 | 2015-04-21 | Ut-Battelle Llc | Method of synthesizing bulk transition metal carbide, nitride and phosphide catalysts |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE132534T1 (en) * | 1986-08-01 | 1996-01-15 | Commw Scient Ind Res Org | RECOMBINANT VACCINE |
EP1026253B2 (en) * | 1989-03-21 | 2012-12-19 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
DE69019609T2 (en) * | 1989-07-07 | 1995-11-30 | Takeda Chemical Industries Ltd | Proteins and their production. |
-
1995
- 1995-07-12 IL IL11457695A patent/IL114576A0/en unknown
- 1995-07-18 CO CO95031727A patent/CO4410257A1/en unknown
- 1995-07-18 CA CA002195099A patent/CA2195099A1/en not_active Abandoned
- 1995-07-18 JP JP8505831A patent/JPH10503649A/en not_active Withdrawn
- 1995-07-18 AU AU31012/95A patent/AU708460B2/en not_active Ceased
- 1995-07-18 HR HR08/279,459A patent/HRP950412A2/en not_active Application Discontinuation
- 1995-07-18 WO PCT/US1995/009057 patent/WO1996003510A1/en not_active Application Discontinuation
- 1995-07-18 EP EP95926736A patent/EP0772680A1/en not_active Withdrawn
- 1995-07-21 ZA ZA956106A patent/ZA956106B/en unknown
- 1995-07-21 YU YU49995A patent/YU49995A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU708460B2 (en) | 1999-08-05 |
EP0772680A1 (en) | 1997-05-14 |
AU3101295A (en) | 1996-02-22 |
WO1996003510A1 (en) | 1996-02-08 |
IL114576A0 (en) | 1995-11-27 |
CA2195099A1 (en) | 1996-02-08 |
CO4410257A1 (en) | 1997-01-09 |
HRP950412A2 (en) | 1997-10-31 |
ZA956106B (en) | 1996-04-10 |
JPH10503649A (en) | 1998-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU734442B2 (en) | Polynucleotide vaccine formula in particular against bovine respiratory pathology | |
ATE85622T1 (en) | CHIMERIC GLYCOPROTEINS CONTAINING IMMUNOGENIC SEGMENTS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS. | |
CN110269932A (en) | African swine fever virus vaccine and application thereof | |
DK1030690T3 (en) | Recombinant vaccines comprising immunogenic attenuated bacteria with RpoS positive phenotype | |
GB8912330D0 (en) | Live vaccines | |
DK0500917T3 (en) | Vaccines and methods based on recombinant herpes simplex viruses. | |
BR9205771A (en) | Recombinant virus vector and process for its manufacture | |
YU49995A (en) | POLYNUCLEOTIDE VACCINE FOR HERPES VIRUS | |
KR970009347B1 (en) | Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3 | |
DE69322092D1 (en) | NEW BACTERIAL VACCINES USING VACCINE STRAINS FROM PATHOGENIC BACTERIA | |
EP0192902A2 (en) | DNA sequences from Varicella-zoster virus, vectors and hosts containing them, the corresponding polypeptides and the compositions containing them | |
HK51597A (en) | Vaccines for human respiratory virus | |
EP0294469A4 (en) | Vaccines and diagnostic assays for haemophilus influenzae. | |
ZA918876B (en) | Avirulent microbes and uses therefor:salmonella typhi | |
CN102089423A (en) | Enhancement of transgene expression from viral-based vaccine vecors by expression of suppressors of the type i interferon response | |
DE69030099T2 (en) | METHOD FOR PRODUCING VACCINE OR TOXOID | |
ES8504254A1 (en) | Production of herpes simplex viral proteins. | |
ATE102650T1 (en) | MUTANTS OF INFECTIOUS BOVIN RHINOTRACCHIE VIRUS, VACCINE CONTAINING THEM, METHODS FOR THEIR PRODUCTION AND THEIR USE. | |
DE69332264T2 (en) | MUTANTS OF THE INFECTIOUS CATTLE RHINOTRACHEITIS VIRUS AND VACCINE | |
Castrucci et al. | Immunization against bovine herpesvirus-1 infection. Preliminary tests in calves with a DNA vaccine | |
GB9404577D0 (en) | Vaccine compositions | |
CN102772793A (en) | Brucella deoxyribonucleic acid (DNA) vaccine as well as construction method and application thereof | |
Amann et al. | High-level production in Escherichia coli of hybrid proteins expressing parts of coding sequences of HSV glycoproteins. | |
ES2074965A1 (en) | Recombinant infectious bovine rhinotracheitis virus mutant, methods for the production of same, and vaccines containing the same. | |
HSV | Patent report |